...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >EFFECT OF FORMULATION FACTORS ON ORODISPERSIBLE TRIPTAN FORMULATIONS – NOVEL APPROACH IN TREATMENT OF MIGRAINE
【24h】

EFFECT OF FORMULATION FACTORS ON ORODISPERSIBLE TRIPTAN FORMULATIONS – NOVEL APPROACH IN TREATMENT OF MIGRAINE

机译:配方因素对口香糖TRIPTAN配方的影响-新型治疗偏头痛的方法

获取原文

摘要

Objective: The present research work is an attempt to determine the effect of various diluents and superdisintegrants on drug release of eletriptan orodispersible tablets and designs an optimized formulation using 22 factorial design. Further, evaluate the tablets for various pre-compression and post-compression parameters. Methods: The drug excipient compatibility study was conducted by infrared spectroscopy, differential scanning colorimetry and X-ray diffraction studies were conducted to test the purity of the drug. The tablets were formulated by direct compression method using spray dried lactose, mannitol, microcrystalline cellulose, starch as diluents and crospovidone, croscarmellose sodium, and sodium starch glycolate as superdisintegrants. The powder formulations were evaluated for pre-compression parameters such as bulk density, tapped density, Carr’s Index, Hausner’s ratio, and angle of repose. The tablets were evaluated for post-compression parameters such as the hardness, thickness, friability, weight variation, and disintegrating time in the oral cavity, in vitro drug release kinetics studies, and accelerated stability studies. The formulations were optimized by 22 factorial design. Results: The drug and excipients were compatible, and no interaction was found. The drug was pure, and all the pre-compression parameters were within Indian Pharmacopoeial Limits. Post-compression parameters were also within limits. The disintegration time was found to be 27 s for the formulation F29 containing Croscarmellose sodium (5%) and Mannitol as diluent, and in vitro drug release was found to be 99.67% in 30 min and follows first-order kinetics. This was also the optimized formulation by 22 factorial design with a p=0.013. Conclusion: The orodispersible tablets of eletriptan were successfully formulated, and the optimized formulation was determined that can be used in the treatment of migraine.
机译:目的:本研究工作旨在确定各种稀释剂和超崩解剂对依曲普坦口服分散片中药物释放的影响,并使用22因子设计设计一种优化配方。此外,评估片剂的各种压缩前和压缩后参数。方法:通过红外光谱,差示扫描比色法和X射线衍射研究进行药物赋形剂相容性研究,以测试药物的纯度。通过直接压片法,使用喷雾干燥的乳糖,甘露醇,微晶纤维素,淀粉作为稀释剂以及交聚维酮,交联羧甲基纤维素钠和羟乙酸淀粉钠作为超崩解剂来配制片剂。对粉末配方的预压缩参数进行了评估,例如堆积密度,堆积密度,卡尔指数,豪斯纳比和休止角。评估片剂的压缩后参数,例如硬度,厚度,脆性,重量变化和在口腔中的崩解时间,体外药物释放动力学研究和加速稳定性研究。通过22因子设计优化配方。结果:药物和赋形剂相容,没有相互作用。该药是纯净的,所有预压缩参数均在印度药典范围内。压缩后参数也在限制范围内。对于包含交联羧甲基纤维素钠(5%)和甘露醇作为稀释剂的制剂F29,崩解时间为27 s,在30分钟内体外药物释放率为99.67%,并遵循一级动力学。这也是通过22因子设计得到的优化配方,p = 0.013。结论:成功制备了依曲曲坦口腔分散片,并确定了最适处方,可用于治疗偏头痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号